Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech to identify and advance novel RNA-targeted small molecule therapeutics.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
Sosei Group Corporation has announced it is regaining the worldwide rights to its muscarinic agonist programs after AbbVie said it is backing away from the program.
Draper, a not-for-profit research and development organization, is speeding the process with new tools designed specifically to produce cell therapies at scale.
The new process development and manufacturing facility will focus on viral vectors and advanced therapies. It is the third location for Diosynth’s CDMO viral vector services.
In the first week of the new year, two companies raised more than $150 million in separate Series A financing rounds to fund research programs aimed at developing treatments for cancer and rare diseases.
With the new year comes a changing of the guard at Pfizer. After two years of helming the company’s pharma operations, Chief Medical Officer Mace Rothenberg announced his departure from Pfizer on social media.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.